Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Salesforce on Wednesday said former Gilead Sciences finance chief Robin Washington will join the software maker to become ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Gilead Sciences ( NASDAQ: GILD) is scheduled to announce Q4 earnings results on Tuesday, February 11th, after market close. Analysts expect a profit of $1.70 per share (-1.2% Y/Y) on revenue of $7.15B ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research ana ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...